{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune&page=21",
    "query": {
      "condition": "Immune",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 22371,
    "total_pages": 2238,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T22:09:42.815Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01363011",
      "title": "Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Immunodeficiency Syndrome",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "E/C/F/TDF",
          "type": "DRUG"
        },
        {
          "name": "COBI",
          "type": "DRUG"
        },
        {
          "name": "ATV",
          "type": "DRUG"
        },
        {
          "name": "DRV",
          "type": "DRUG"
        },
        {
          "name": "NRTI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2011-05",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-05-02",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01363011"
    },
    {
      "nct_id": "NCT06977711",
      "title": "Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Loncastuximab",
          "type": "DRUG"
        },
        {
          "name": "Roflumilast",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-06-20",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06977711"
    },
    {
      "nct_id": "NCT02434757",
      "title": "Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "H.P. Acthar Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ronald J. Rapoport, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-02",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2015-05-05",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 1,
      "location_summary": "Fall River, Massachusetts",
      "locations": [
        {
          "city": "Fall River",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02434757"
    },
    {
      "nct_id": "NCT04150328",
      "title": "Lenalidomide Monotherapy in R/R DLBCL",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "MorphoSys AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2019-04-12",
      "completion_date": "2020-08-25",
      "has_results": false,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 8,
      "location_summary": "Rochester, Minnesota • St Louis, Missouri • Manhasset, New York + 5 more",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04150328"
    },
    {
      "nct_id": "NCT07271667",
      "title": "A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "B-cell Malignancies"
      ],
      "interventions": [
        {
          "name": "Emavusertib",
          "type": "DRUG"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Curis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2026-04-23",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 6,
      "location_summary": "Miami Beach, Florida • Rochester, Minnesota • Florham Park, New Jersey + 3 more",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Florham Park",
          "state": "New Jersey"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07271667"
    },
    {
      "nct_id": "NCT00062244",
      "title": "Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "oblimersen sodium",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2003-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062244"
    },
    {
      "nct_id": "NCT01816971",
      "title": "Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2013-01",
      "completion_date": "2026-03-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01816971"
    },
    {
      "nct_id": "NCT05157971",
      "title": "Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia",
        "Ph-Like Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "18 Years to 54 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-03-17",
      "completion_date": "2027-04-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05157971"
    },
    {
      "nct_id": "NCT02194998",
      "title": "Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)",
          "type": "DRUG"
        },
        {
          "name": "Dasabuvir (DSV)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 46,
      "start_date": "2015-09-16",
      "completion_date": "2018-11-13",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02194998"
    },
    {
      "nct_id": "NCT04684563",
      "title": "huCART19-IL18 in CD19+ Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non-hodgkin Lymphoma",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "huCART19-IL18",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2021-05-06",
      "completion_date": "2036-05",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-28T22:09:42.815Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684563"
    }
  ]
}